Clinical Trial

Met Non Small Cell Cancer Registry (MOMENT)

Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time. The registry will capture data on participants; demographic, clinical characteristics (including biomarker data), treatment patterns, and effectiveness and safety outcomes for advanced NSCLC with mesenchymal-epithelial transition exon 14(METex14) participants treated with systemic therapy.
Protocol Amendment History 35 amendments
This ClinicalTrials.gov record has been amended 35 times since 2022-05-11; most recent amendment 2026-07-10.
Status change: Not Yet Recruiting → Recruiting 2022-11-03
Trial Details
NCT Number NCT05376891
Lead Sponsor EMD Serono Research & Development Institute, Inc.
Collaborators: Merck KGaA, Darmstadt, Germany
Conditions Cancer
Enrollment 700 participants
Start Date 2022-10-04
Primary Completion 2028-04-28 (estimated)
Study Completion 2028-04-28 (estimated)
Updated on ClinicalTrials.gov 2026-07-13